<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672878</url>
  </required_header>
  <id_info>
    <org_study_id>RIBS VI</org_study_id>
    <nct_id>NCT02672878</nct_id>
  </id_info>
  <brief_title>Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)</brief_title>
  <acronym>RIBS VI</acronym>
  <official_title>Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Terumo Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with in-stent restenosis (ISR) remains a challenge. This study will
      assess the efficacy of Bioresorbable Vascular Scaffolds (BVS) (Abbott Vascular) in the
      treatment of patients suffering from ISR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of patients with ISR remains a challenge. Currently both drug-eluting stents (DES)
      and drug-coated balloons (DCB) are considered as the strategies of choice in this setting.
      However, data on the value of BVS in patients with ISR is scarce. BVS are very effective to
      inhibit neointimal proliferation and they avoid the need of implanting a new permanent metal
      layer. Accordingly, currently, there is a major interest to elucidate the potential value of
      BVS in patients with ISR.

      This prospective Spanish multicenter study will assess the clinical and angiographic outcome
      of patients with ISR treated with BVS. BVS will be implanted in selected patients (fulfilling
      inclusion and exclusion criteria) presenting with either BMS-ISR or DES-ISR. Care will be
      paid to ensure device optimization. Angiographic follow-up will be obtained at 6-9 months. A
      centralized angiographic corelab will be used to provide QCA measurements. Clinical follow-up
      will be also obtained at 1 year and then yearly. Clinical events will be adjudicated by an
      independent Clinical Event Committee.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal lumen diameter as assessed by quantitative coronary angiography at late angiographic follow-up</measure>
    <time_frame>angiographic follow-up at 6-9 months</time_frame>
    <description>This is a single arm study and results will be analyzed per arm. However, the angiographic and clinical results will be also compared with those obtained in other arms of previous RIBS trials</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined clinical end-point (cardiac death, myocardial infarction and target vessel revascularization)</measure>
    <time_frame>1 year of clinical follow-up</time_frame>
    <description>This is a well-accepted outcome measure of individual clinical end-points. Definition of myocardial infarction is similar to that used in previous RIBS studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute gain</measure>
    <time_frame>procedure</time_frame>
    <description>Change in the minimal lumen diameter from baseline to the final procedural angiogram. Acute angiographic parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal lumen diameter</measure>
    <time_frame>procedure</time_frame>
    <description>Acute angiographic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent diameter stenosis</measure>
    <time_frame>procedure</time_frame>
    <description>Acute angiographic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate</measure>
    <time_frame>6-9 months</time_frame>
    <description>Late angiographic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent diameter stenosis</measure>
    <time_frame>6-9 months</time_frame>
    <description>Late angiographic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late loss</measure>
    <time_frame>6-9 months</time_frame>
    <description>Change in minimal lumen diameter from the final procedure to the follow-up angiogram at 6-9 months. Late angiographic parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net gain</measure>
    <time_frame>6-9 months</time_frame>
    <description>Is the difference between acute gain and late loss. Late angiographic parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss index</measure>
    <time_frame>6-9 months</time_frame>
    <description>Late angiographic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined clinical outcome measure (Cardiac death, Myocardial infarction, target lesion revascularization)</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>This is a well-accepted outcome measure of individual clinical end-points. Definition of myocardial infarction is similar to that used in previous RIBS studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Individual clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Individual clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Individual clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Individual clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Individual clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Individual clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Individual clinical outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Coronary In-stent Restenosis</condition>
  <arm_group>
    <arm_group_label>BVS implantation in patients with ISR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable vascular scaffold</intervention_name>
    <arm_group_label>BVS implantation in patients with ISR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        In-stent restenosis with ischemia. Signed Informed Consent IRB approval

        INCLUSION CRITERIA:

        PATIENT

          -  Age &gt; 20 and &lt; 85 years of age

          -  Acceptance of late angiographic evaluation

          -  Angina or objective evidence of ischemia

        LESION

          -  ISR (&gt;50% diameter stenosis on visual assessment)

          -  Previous stent location known

        EXCLUSION CRITERIA:

        PATIENT

          -  Inclusion in other clinical research protocol

          -  Allergy to antiplatelet agents

          -  Women in childbearing age

          -  Severe associated systemic diseases (including renal or liver failure) or diseases
             affecting life expectancy

          -  Recent myocardial infarction

          -  Time from index stent implantation &lt; 1 month

          -  Anticipated difficulties for late angiographic evaluation

        LESION

          -  Stent thrombosis or large thrombus within the stent

          -  Angiographic failure during initial stent implantation or persistence or large
             dissection.

          -  Severe tortuosity or calcification or major difficulties during previous stent
             implantation

          -  Vessel diameter &lt; 2.25 mm (visual assessment)

          -  Stenosis outside stent stent edge (edge ISR are eligible)

          -  Very diffuse ISR (&gt;30 mm in length)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Complexo Universitario Hospitalario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramiro Trillo, MD</last_name>
      <email>ramirotrillo@mac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel del Valle, MD</last_name>
      <email>raqueldelvalle@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L´Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Romaguera, MD</last_name>
      <email>rafaromaguera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Zueco, MD</last_name>
      <email>jzueco@humv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arturo Garcia-Touchard, MD</last_name>
      <email>agtouchard@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>San Cristobal de La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Ignacio Ga Bosa, MD</last_name>
      <email>franbosa@ull.edu.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Ramón López Minguez, MD</last_name>
      <email>lopez-minguez@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicens Marti, MD</last_name>
      <email>vmarti@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Imanol Otaeghi, MD</last_name>
      <email>iotaegui@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Masotti, MD</last_name>
      <email>masotti@clinic.ub.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Melgares, MD</last_name>
      <email>rafael.melgares.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de León</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armando Pérez, MD</last_name>
      <email>aperez@secardiologia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Alfonso Manterola, MD, PhD</last_name>
      <email>falf@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Javier Cuesta Cuesta, MD</last_name>
      <email>javicuestacuesta@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosana Hernández, MD</last_name>
      <email>rhernandez_antolin@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maite Velazquez, MD</last_name>
      <email>maitevel05@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raúl Moreno, MD</last_name>
      <email>raulmorenog@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Moreu, MD</last_name>
      <email>jmoreu@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hipólito Gutierrez, MD</last_name>
      <email>hggmaire@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Vizcaya</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Ramón Rumoroso, MD</last_name>
      <email>rumo@secardiologia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Minguez JR, Angel J, Augé JM, Gómez-Recio M, Morís C, Seabra-Gomes R, Perez-Vizcayno MJ, Macaya C; Restenosis Intra-stent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003 Sep 3;42(5):796-805.</citation>
    <PMID>12957423</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Melgares R, Mainar V, Lezaún R, Vázquez N, Tascón J, Pomar F, Cequier A, Angel J, Pérez-Vizcayno MJ, Sabaté M, Bañuelos C, Fernández C, García JM; Restensois Intra-stent: Ballon angioplasty versus elective Stenting (RIBS) Investigators. Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. Eur Heart J. 2004 Oct;25(20):1829-35.</citation>
    <PMID>15474698</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Augé JM, Zueco J, Bethencourt A, López-Mínguez JR, Hernández JM, Bullones JA, Calvo I, Esplugas E, Pérez-Vizcayno MJ, Moreno R, Fernández C, Hernández R, Gama-Ribeiro V; RIBS Investigators. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol. 2005 Sep 6;46(5):756-60.</citation>
    <PMID>16139121</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Gómez-Recio M, Insa L, Calvo I, Hernández JM, Bullones JA, Hernández R, Escaned J, Macaya C, Gama-Ribeiro V, Leitao-Marques A; Restenosis Intrastent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. Implications of the &quot;watermelon seeding&quot; phenomenon during coronary interventions for in-stent restenosis. Catheter Cardiovasc Interv. 2005 Dec;66(4):521-7.</citation>
    <PMID>16261546</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Cequier A, Angel J, Martí V, Zueco J, Bethencourt A, Mantilla R, López-Minguez JR, Gómez-Recio M, Morís C, Perez-Vizcayno MJ, Fernández C, Macaya C, Seabra-Gomes R; Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) Investigators. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial. Am Heart J. 2006 Mar;151(3):681.e1-681.e9.</citation>
    <PMID>16504631</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Bethencourt A, Martí V, López-Mínguez JR, Angel J, Mantilla R, Morís C, Cequier A, Sabaté M, Escaned J, Moreno R, Bañuelos C, Suárez A, Macaya C; RIBS-II Investigators. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006 Jun 6;47(11):2152-60.</citation>
    <PMID>16750678</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Fernandez C, Escaned J, Bañuelos C, Bethencourt A, López-Mínguez JR, Angel J, Cequier A, Sabaté M, Morís C, Zueco J, Seabra-Gomes R; Restenosis Intra-Stent: Balloon Angioplasty Versus Elective Stent Implantation (RIBS-I) and Restenosis Intra-Stent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Investigators. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv. 2008 Oct 1;72(4):459-67. doi: 10.1002/ccd.21694.</citation>
    <PMID>18814274</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Hernández R, Bethencourt A, Martí V, López-Mínguez JR, Angel J, Iñiguez A, Morís C, Cequier A, Sabaté M, Escaned J, Jiménez-Quevedo P, Bañuelos C, Suárez A, Macaya C; RIBS-II Investigators. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol. 2008 Nov 11;52(20):1621-7. doi: 10.1016/j.jacc.2008.08.025.</citation>
    <PMID>18992651</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, Martí V, Lozano I, Angel J, Hernández JM, López-Mínguez JR, Melgares R, Moreno R, Seidelberger B, Fernández C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv. 2012 Jul;5(7):728-37. doi: 10.1016/j.jcin.2012.03.017.</citation>
    <PMID>22814777</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014 Apr 15;63(14):1378-86. doi: 10.1016/j.jacc.2013.12.006. Epub 2014 Jan 8.</citation>
    <PMID>24412457</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, García-Touchard A, López-Minguéz JR, Rivero F, Masotti M, Zueco J, Cequier A, Morís C, Fernández-Ortíz A, Escaned J, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; Restenosis Intra-stent: drug-eluting Balloon vs. everolimus-eluting Stent (RIBS IV) Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis). EuroIntervention. 2015 Jul;11(3):336-42. doi: 10.4244/EIJY14M09_07.</citation>
    <PMID>25244700</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, Benedicto A, Masotti M, Zueco J, Iñiguez A, Velázquez M, Moreno R, Mainar V, Domínguez A, Pomar F, Melgares R, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS IV Study Investigators (under auspices of Interventional Cardiology Working Group of Spanish Society of Cardiology). A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 2015 Jul 7;66(1):23-33. doi: 10.1016/j.jacc.2015.04.063.</citation>
    <PMID>26139054</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Cardiology</investigator_affiliation>
    <investigator_full_name>Fernando Alfonso</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>In-stent restenosis</keyword>
  <keyword>Bioresorbable vascular scaffold</keyword>
  <keyword>Stent</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Coronary angiography</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

